Tenderwize
Wróć do wyszukiwania

Non-exclusive rebate agreement for Aclidiniumbromid

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 29, 2028 · 551 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Aclidiniumbromid (ATC-Code nach WHO: R03BB05)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice says participation documents must be submitted via the DTVP communication function, while also stating that...

Only the first participation deadline is explicitly stated in the extracted text; further deadlines are in a missing at...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Non-exclusive rebate agreements for pharmaceutical products containing Aclidiniumbromid (ATC R03BB05).
  • Open-House model: any interested eligible pharmaceutical company may join during the participation period.
Pokaż pełne podsumowanie

This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements under §130a(8) SGB V for the active substance Aclidiniumbromid (ATC R03BB05). The lead buyer is AOK PLUS. No contract value is stated; demand and minimum purchase volumes are explicitly not guaranteed. Participation is open to all eligible pharmaceutical companies during the participation period, with electronic communication via DTVP and no electronic submission via the bidder tool. The notice and XML contain some inconsistencies on dates and submission mechanics, but the core scope and Open-House nature are clear.

Ryzyka

The notice says participation documents must be submitted via the DTVP communication function, while also stating that...

Only the first participation deadline is explicitly stated in the extracted text; further deadlines are in a missing at...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal products.

Eligibility

  • Submission of the completed declaration on the absence of exclusion grounds is required.

Administrative

  • The company must meet the participation requirements in the documents 'Anschreiben' and 'Erläuterungen der Vertragsbedingungen'.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive rebate agreement for Aclidiniumbromid

Open-House supply lot for non-exclusive pharmaceutical rebate agreements for medicines containing Aclidiniumbromid (ATC R03BB05). Scope is limited to the named active substance; no exclusivity, no individual negotiations, and no guaranteed minimum purchase volume. Place of performance is Dresden, Germany, with performance covering Germany and the federal states of Saxony and Thuringia as stated in the XML notice.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Feb 2026 - Feb 2028

Kategoria

Pharmaceutical products

Termin

Expired Feb 03, 2026

Szczegóły zamówienia

Data publikacji
23 Dec 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
862508-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3